- Home
- GNLX vs CSBR Comparison
GNLX vs CSBR Comparison
Compare GNLX & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- CSBR
- Stock Information
- Founded
- GNLX 2001
- CSBR 1985
- Country
- GNLX United States
- CSBR United States
- Employees
- GNLX N/A
- CSBR N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GNLX Health Care
- CSBR Health Care
- Exchange
- GNLX Nasdaq
- CSBR Nasdaq
- Market Cap
- GNLX 129.9M
- CSBR 123.2M
- IPO Year
- GNLX 2023
- CSBR 1986
- Fundamental
- Price
- GNLX $3.53
- CSBR $6.41
- Analyst Decision
- GNLX Strong Buy
- CSBR Strong Buy
- Analyst Count
- GNLX 5
- CSBR 1
- Target Price
- GNLX $16.20
- CSBR $12.00
- AVG Volume (30 Days)
- GNLX 153.8K
- CSBR 34.8K
- Earning Date
- GNLX 08-13-2025
- CSBR 07-23-2025
- Dividend Yield
- GNLX N/A
- CSBR N/A
- EPS Growth
- GNLX N/A
- CSBR N/A
- EPS
- GNLX N/A
- CSBR 0.33
- Revenue
- GNLX N/A
- CSBR $56,944,000.00
- Revenue This Year
- GNLX N/A
- CSBR $9.30
- Revenue Next Year
- GNLX N/A
- CSBR $31.17
- P/E Ratio
- GNLX N/A
- CSBR $19.48
- Revenue Growth
- GNLX N/A
- CSBR 13.54
- 52 Week Low
- GNLX $1.60
- CSBR $3.60
- 52 Week High
- GNLX $5.89
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- GNLX 58.36
- CSBR 36.73
- Support Level
- GNLX $3.30
- CSBR $6.06
- Resistance Level
- GNLX $3.60
- CSBR $6.94
- Average True Range (ATR)
- GNLX 0.26
- CSBR 0.61
- MACD
- GNLX 0.00
- CSBR -0.25
- Stochastic Oscillator
- GNLX 75.71
- CSBR 11.99
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.